<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Venlafaxine for neuropathic pain in adults - Gallagher, HC - 2015 | Cochrane Library</title> <meta content="Venlafaxine for neuropathic pain in adults - Gallagher, HC - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011091.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Venlafaxine for neuropathic pain in adults - Gallagher, HC - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011091.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011091.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Venlafaxine for neuropathic pain in adults" name="citation_title"/> <meta content="Helen C Gallagher" name="citation_author"/> <meta content="University College Dublin" name="citation_author_institution"/> <meta content="helen.gallagher@ucd.ie" name="citation_author_email"/> <meta content="Ruth M Gallagher" name="citation_author"/> <meta content="Princess of Wales Hospital" name="citation_author_institution"/> <meta content="Michelle Butler" name="citation_author"/> <meta content="The University of British Columbia" name="citation_author_institution"/> <meta content="Donal J Buggy" name="citation_author"/> <meta content="Martin C Henman" name="citation_author"/> <meta content="Trinity College Dublin" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD011091.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/08/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011091.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011091.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011091.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; Antidepressive Agents, Second‐Generation [adverse effects, *therapeutic use]; Carbamazepine [therapeutic use]; Imipramine [therapeutic use]; Neuralgia [*drug therapy]; Off‐Label Use; Patient Dropouts; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011091.pub2&amp;doi=10.1002/14651858.CD011091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011091\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011091\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011091.pub2",title:"Venlafaxine for neuropathic pain in adults",firstPublishedDate:"Aug 23, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011091.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011091.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011091.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011091.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011091.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011091.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011091.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011091.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011091.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011091.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5907 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011091.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-sec-0073"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-sec-0051"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/appendices#CD011091-sec-0085"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Venlafaxine for neuropathic pain in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information#CD011091-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Helen C Gallagher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information#CD011091-cr-0003">Ruth M Gallagher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information#CD011091-cr-0004">Michelle Butler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information#CD011091-cr-0005">Donal J Buggy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information#CD011091-cr-0006">Martin C Henman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information/en#CD011091-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 August 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011091.pub2">https://doi.org/10.1002/14651858.CD011091.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011091-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011091-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011091-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011091-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011091-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011091-abs-0001" lang="en"> <section id="CD011091-sec-0001"> <h3 class="title" id="CD011091-sec-0001">Background</h3> <p>Neuropathic pain, which is caused by nerve damage, is increasing in prevalence worldwide. This may reflect improved diagnosis, or it may be due to increased incidence of diabetes‐associated neuropathy, linked to increasing levels of obesity. Other types of neuropathic pain include post‐herpetic neuralgia, trigeminal neuralgia, and neuralgia caused by chemotherapy. Antidepressant drugs are sometimes used to treat neuropathic pain; however, their analgesic efficacy is unclear. A previous Cochrane review that included all antidepressants for neuropathic pain is being replaced by new reviews of individual drugs examining chronic neuropathic pain in the first instance. Venlafaxine is a reasonably well‐tolerated antidepressant and is a serotonin reuptake inhibitor and weak noradrenaline reuptake inhibitor. Although not licensed for the treatment of chronic or neuropathic pain in most countries, it is sometimes used for this indication. </p> </section> <section id="CD011091-sec-0002"> <h3 class="title" id="CD011091-sec-0002">Objectives</h3> <p>To assess the analgesic efficacy of, and the adverse effects associated with the clinical use of, venlafaxine for chronic neuropathic pain in adults. </p> </section> <section id="CD011091-sec-0003"> <h3 class="title" id="CD011091-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) via <i>The Cochrane Library</i>, and MEDLINE and EMBASE via Ovid up to 14 August 2014. We reviewed the bibliographies of any randomised trials identified and review articles, contacted authors of one excluded study and searched www.clinicaltrials.gov to identify additional published or unpublished data. We also searched the meta‐Register of controlled trials (mRCT) (www.controlled‐trials.com/mrct) and the WHO International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/) for ongoing trials but did not find any relevant trials. </p> </section> <section id="CD011091-sec-0004"> <h3 class="title" id="CD011091-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind studies of at least two weeks' duration comparing venlafaxine with either placebo or another active treatment in chronic neuropathic pain in adults. All participants were aged 18 years or over and all included studies had at least 10 participants per treatment arm. We only included studies with full journal publication. </p> </section> <section id="CD011091-sec-0005"> <h3 class="title" id="CD011091-sec-0005">Data collection and analysis</h3> <p>Three review authors independently extracted data using a standard form and assessed study quality. We intend to analyse data in three tiers of evidence as described by Hearn 2014, but did not find any first‐tier evidence (ie evidence meeting current best standards, with minimal risk of bias) or second‐tier evidence, that was considered at some risk of bias but with adequate participant numbers (at least 200 in the comparison). Third‐tier evidence is that arising from studies with small numbers of participants; studies of short duration, studies that are likely to be of limited clinical utility due to other limitations, including selection bias and attrition bias; or a combination of these. </p> </section> <section id="CD011091-sec-0006"> <h3 class="title" id="CD011091-sec-0006">Main results</h3> <p>We found six randomised, double‐blind trials of at least two weeks' duration eligible for inclusion. These trials included 460 participants with neuropathic pain, with most participants having painful diabetic neuropathy. Four studies were of cross‐over design and two were parallel trials. Only one trial was both parallel design and placebo‐controlled. Mean age of participants ranged from 48 to 59 years. In three studies (Forssell 2004, Jia 2006 and Tasmuth 2002), only mean data were reported. Comparators included placebo, imipramine, and carbamazepine and duration of treatment ranged from two to eight weeks. The risk of bias was considerable overall in the review, especially due to the small size of most studies and due to attrition bias. Four of the six studies reported some positive benefit for venlafaxine. In the largest study by Rowbotham, 2004, 56% of participants receiving venlafaxine 150 to 225 mg achieved at least a 50% reduction in pain intensity versus 34% of participants in the placebo group and the number needed to treat for an additional beneficial outcome was 4.5. However, this study was subject to significant selection bias. Known adverse effects of venlafaxine, including somnolence, dizziness, and mild gastrointestinal problems, were reported in all studies but were not particularly problematic and, overall, adverse effects were equally prominent in placebo or other active comparator groups. </p> </section> <section id="CD011091-sec-0007"> <h3 class="title" id="CD011091-sec-0007">Authors' conclusions</h3> <p>We found little compelling evidence to support the use of venlafaxine in neuropathic pain. While there was some third‐tier evidence of benefit, this arose from studies that had methodological limitations and considerable risk of bias. Placebo effects were notably strong in several studies. Given that effective drug treatments for neuropathic pain are in current use, there is no evidence to revise prescribing guidelines to promote the use of venlafaxine in neuropathic pain. Although venlafaxine was generally reasonably well tolerated, there was some evidence that it can precipitate fatigue, somnolence, nausea, and dizziness in a minority of people. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011091-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011091-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011091-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011091-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011091-abs-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011091-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011091-abs-0002" lang="en"> <h3>Venlafaxine for neuropathic pain in adults</h3> <p><b>Background</b> </p> <p>Neuropathic pain is pain that arises from damaged nerves. It is different in nature than pain that arises from damaged tissue, such as a cut, although that type of pain is also carried along nerves. Drugs that are commonly used to treat pain, such as paracetamol, ibuprofen, or morphine, are not very good at treating neuropathic pain. However, other drugs, such as gabapentin, which are also used to prevent or treat epilepsy (fits), do appear to be of some benefit in treating neuropathic pain. There is also a great deal of interest in using antidepressant drugs to treat neuropathic pain. This does not imply that the person with neuropathic pain is depressed, but simply that these drugs may have benefits in neuropathic pain. However, while some doctors prescribe antidepressants in people with neuropathic pain, their benefits have not been confirmed in large clinical trials. </p> <p>Here we reviewed clinical trials for one antidepressant drug, venlafaxine, to see if robust evidence exists that it is effective in treating neuropathic pain. </p> <p><b>Study characteristics</b> </p> <p>In detailed searches of the medical literature, we found six trials that were suitable for inclusion in our analysis, that together included 460 adults. </p> <p><b>Key results and quality of the evidence</b> </p> <p>All six trials were conducted in an approved statistical manner (randomised and double‐blinded); however, all had limitations that could lead to an overestimation of efficacy in treating this type of pain. Four were of very small size and five were of short duration, both of which can bias the results of chronic pain trials. Although it was not possible to combine the results of all trials to make an overall conclusion, individually they did all show some, albeit moderate, benefit for venlafaxine in treating neuropathic pain. Usually this benefit was achieved at doses of 75 to 225 mg per day. Known side effects of venlafaxine, including sleepiness, dizziness, and mild gastrointestinal problems, were reported by some studies, but were not particularly problematic. </p> <p>Overall, there is currently an inadequate amount of information available to warrant any change in current prescribing practice and we cannot recommend venlafaxine as a first‐line treatment for neuropathic pain. However, it is a reasonably well‐tolerated drug and may be of some benefit in people who cannot tolerate other antidepressants or anticonvulsant drugs that are more widely prescribed to people with neuropathic pain. Larger clinical trials may provide more robust evidence for the effectiveness of venlafaxine in treating neuropathic pain. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011091-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011091-sec-0073"></div> <h3 class="title" id="CD011091-sec-0074">Implications for practice</h3> <section id="CD011091-sec-0074"> <section id="CD011091-sec-0075"> <h5 class="title">Implications for people with neuropathic pain</h5> <p>This review is unlikely to change clinical practice in a manner that will improve outcomes for people with neuropathic pain. Our results suggested that, for the vast majority of people with neuropathic pain, there is insufficient evidence to support the use of a venlafaxine‐based intervention in the current standard of care. </p> </section> <section id="CD011091-sec-0076"> <h5 class="title">Implications for clinicians</h5> <p>There is little compelling evidence to support the use of venlafaxine in neuropathic pain except by experienced clinicians in exceptional circumstances. </p> </section> <section id="CD011091-sec-0077"> <h5 class="title">Implications for practice for policy makers</h5> <p>Any evidence for venlafaxine's benefit in treating neuropathic pain is not sufficiently robust to warrant any change in policy regarding its licensed indications. </p> </section> <section id="CD011091-sec-0078"> <h5 class="title">Implications for practice for funders</h5> <p>Although this review found some evidence to support the use of venlafaxine in treating neuropathic pain, overall this evidence was of low quality. From a pharmacoeconomic perspective, there is insufficient evidence to support a change in reimbursement practice. </p> </section> </section> <h3 class="title" id="CD011091-sec-0079">Implications for research</h3> <section id="CD011091-sec-0079"> <section id="CD011091-sec-0080"> <h5 class="title">General</h5> <p>Larger, prospective well‐designed studies are required to provide more definitive conclusions on the efficacy of venlafaxine for treating neuropathic pain. While we hope these will be performed, there is no guarantee that this will occur </p> </section> <section id="CD011091-sec-0081"> <h5 class="title">Design</h5> <p>Double‐blind, randomised, placebo‐controlled trials with over 200 participants per treatment arm and treatment period of at least eight weeks would be more conclusive if further evidence for the efficacy of venlafaxine in treating neuropathic pain is to be obtained. We believe that there is little value in the conduct of future small trials or case series. </p> </section> <section id="CD011091-sec-0082"> <h5 class="title">Measurement (endpoints)</h5> <p>Current best standards, where studies report the outcome of at least 50% pain intensity reduction over baseline (or its equivalent), without the use of last observation carried forward (LOCF) or other imputation methods for drop‐out, should be adopted to provide first‐tier evidence in future trials. Furthermore, in future clinical studies it would be most beneficial if mean data were not reported so that proper estimates can be made of the proportion of participants benefiting from venlafaxine treatment. </p> </section> <section id="CD011091-sec-0083"> <h5 class="title">Other</h5> <p>Further research studies on the mechanism of action of venlafaxine in treating neuropathic pain are also warranted. </p> </section> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011091-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011091-sec-0022"></div> <p>We have based the protocol for this review on a template for reviews of drugs used to relieve neuropathic pain. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD011091-bbs2-0045" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: doi:10.1016/j.pain.2010.05.011] '>Moore 2010a</a>; <a href="./appendices#CD011091-sec-0086">Appendix 1</a>). </p> <section id="CD011091-sec-0023"> <h3 class="title" id="CD011091-sec-0023">Description of the condition</h3> <p>Neuropathic pain, unlike nociceptive pain, is caused by nerve damage, often accompanied by changes in the central nervous system (CNS) (<a href="./references#CD011091-bbs2-0031" title="IannettiGD , ZambreanuL , WiseRG , BuchananTJ , HugginsJP , SmartTS , et al. Pharmacological modulation of pain‐related brain activity during normal and central sensitization states in humans. Proceedings of the National Academy of Sciences of the United States of America2005;102:18195‐200. ">Iannetti 2005</a>). It is by nature chronic and may be present for months or years. The 2011 definition of neuropathic pain is "pain caused by a lesion or disease of the somatosensory system" (<a href="./references#CD011091-bbs2-0033" title="JensenTS , BaronR , HaanpääM , KalsoE , LoeserJD , RiceAS , et al. A new definition of neuropathic pain. Pain2011;152(10):2204‐5. [DOI: 10.1016/j.pain.2011.06.017] ">Jensen 2011</a>). Many people with neuropathic pain are significantly disabled, with moderate or severe pain for many years. </p> <p>In primary care in the UK, the incidences per 100,000 person‐years' observation were reported as 28 (95% confidence interval (CI) 27 to 30) for postherpetic neuralgia, 27 (95% CI 26 to 29) for trigeminal neuralgia, 0.8 (95% CI 0.6 to 1.1) for phantom limb pain, and 21 (95% CI 20 to 22) for painful diabetic neuropathy (<a href="./references#CD011091-bbs2-0028" title="HallGC , CarrollD , McQuayHJ . Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice2008;9:26. [DOI: 10.1186/1471‐2296‐9‐26] ">Hall 2008</a>). Estimates vary between studies, often because of small numbers of cases. The incidence of trigeminal neuralgia has been estimated at 4 in 100,000 per year (<a href="./references#CD011091-bbs2-0034" title="KatusicS , WilliamsDB , BeardCM , BergstralhEJ , KurlandLT . Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945‐1984. Neuroepidemiology1991;10:276‐81. ">Katusic 1991</a>; <a href="./references#CD011091-bbs2-0058" title="RappaportZH , DevorM . Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain1994;56:127‐38. [DOI: 10.1016/0304‐3959(94)90086‐8] ">Rappaport 1994</a>), while more recently a study of facial pain in The Netherlands found incidences per 100,000 person‐years of 12.6 for trigeminal neuralgia and 3.9 for postherpetic neuralgia (<a href="./references#CD011091-bbs2-0035" title="KoopmanJS , DielemanJP , HuygenFJ , deMosM , MartinCG , SturkenboomMC . Incidence of facial pain in the general population. Pain2009;147(1‐3):122‐7. [DOI: 10.1016/j.pain.2009.08.023] ">Koopman 2009</a>). A systematic review of chronic pain demonstrated that some neuropathic pain conditions, such as painful diabetic neuropathy, can be more common, with prevalence rates up to 400 per 100,000 person‐years (<a href="./references#CD011091-bbs2-0040" title="McQuayHJ , SmithLA , MooreRA . Chronic pain. In: StevensA , RafteryJ , MantJ , SimpsonS editor(s). Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007. [ISBN: 978‐1‐84619‐063‐6] ">McQuay 2007</a>). The prevalence of neuropathic pain was reported as being 3.3% in Austria (<a href="./references#CD011091-bbs2-0027" title="GustorffB , DornerT , LikarR , GrisoldW , LawrenceK , SchwarzF , et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica2008;52(1):132‐6. [DOI: 10.1111/j.1399‐6576.2007.01486.x] ">Gustorff 2008</a>), 6.9% in France (<a href="./references#CD011091-bbs2-0022" title="BouhassiraD , Lantéri‐MinetM , AttalN , LaurentB , TouboulC . Prevalence of chronic pain with neuropathic characteristics in the general population. Pain2008;136(3):380‐7. [DOI: 10.1016/j.pain.2007.08.013] ">Bouhassira 2008</a>), and as high as 8% in the UK (<a href="./references#CD011091-bbs2-0066" title="TorranceN , SmithBH , BennettMI , LeeAJ . The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain2006;7(4):281‐9. [DOI: 10.1016/j.jpain.2005.11.008] ">Torrance 2006</a>). Some forms of neuropathic pain, such as diabetic neuropathy, chemotherapy‐related neuralgia, and postsurgical chronic pain (which is often neuropathic in origin) are increasing (<a href="./references#CD011091-bbs2-0028" title="HallGC , CarrollD , McQuayHJ . Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice2008;9:26. [DOI: 10.1186/1471‐2296‐9‐26] ">Hall 2008</a>). Although incidence rates for neuropathic pain have not been accurately reported in Ireland, results from the PRIME study (Prevalence, Impact and Cost of Chronic Pain) suggest a prevalence of 36% for chronic pain in the community setting (<a href="./references#CD011091-bbs2-0057" title="RafteryMN , SarmaK , MurphyAW , De laHarpeD , NormandC , McGuireBE . Chronic pain in the Republic of Ireland ‐ community prevalence, psychosocial profile and predictors of pain‐related disability: results from the Prevalence, Impact and Cost of Chronic Pain (PRIME) study, part 1. Pain2011;152(5):1096‐103. [DOI: 10.1016/j.pain.2011.01.019; PUBMED: 21450402] ">Raftery 2011</a>). It is likely that a significant proportion of these people have pain of neuropathic origin. </p> <p>Neuropathic pain is difficult to treat effectively, with only a minority of individuals experiencing a clinically relevant benefit from any one intervention. Thus, it constitutes a significant burden on healthcare systems and society at large, as well as being distressing for individual patients (<a href="./references#CD011091-bbs2-0052" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2014; Vol. 14, issue 1:79‐94. [DOI: 10.1111/papr.12050] ">Moore 2014</a>). A multidisciplinary approach is now advocated, with pharmacological interventions being combined with physical or cognitive interventions, or both. Conventional analgesics are usually not effective, although opioids may be in some people. However, the risks of using opioids chronically to control pain tend to outweigh their benefits. Other people may derive some benefit from topical lidocaine patches or topical capsaicin. Treatment is more usually by so‐called 'unconventional' analgesics, such as antidepressants or antiepileptics. </p> </section> <section id="CD011091-sec-0024"> <h3 class="title" id="CD011091-sec-0024">Description of the intervention</h3> <p>The antidepressant agent venlafaxine is a serotonin reuptake inhibitor and weak noradrenaline reuptake inhibitor. It is used in the treatment and prevention of recurrence of major depressive disorder, as well as in the treatment of generalised anxiety disorder, social anxiety disorder, panic disorder, and agoraphobia. Although not licensed in Ireland (or the UK) for the treatment of chronic or neuropathic pain, it is commonly used for these indications. The drug is available as prolonged‐release capsules (37.5, 75, and 150 mg) suitable for once daily dosing. For the treatment and prevention of depression, the recommended starting dose for prolonged‐release venlafaxine is 75 mg given once daily. People not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Common adverse effects include nausea, dizziness, drowsiness, and dry mouth. As with other serotonergic agents, serotonin syndrome, a potentially life‐threatening condition, may occur as an adverse effect of venlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system. Suicide‐related behaviours, mydriasis (dilated pupils), and dose‐related increases in blood pressure and heart rate have also been reported with venlafaxine. </p> </section> <section id="CD011091-sec-0025"> <h3 class="title" id="CD011091-sec-0025">How the intervention might work</h3> <p>Venlafaxine is a chimeric compound and both R‐ and S‐enantiomers, and their O‐desmethylated metabolites, are reported to mediate inhibition of serotonin and noradrenaline reuptake (<a href="./references#CD011091-bbs2-0021" title="Bolden‐WatsonC , RichelsonE . Blockade by newly‐developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences1993;52(12):1023‐9. [PUBMED: 8445992] ">Bolden‐Watson 1993</a>; <a href="./references#CD011091-bbs2-0053" title="MuthEA , HaskinsJT , MoyerJA , HusbandsGE , NielsenST , SiggEB . Antidepressant biochemical profile of the novel bicyclic compound Wy‐45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology1986;35(24):4493‐7. [DOI: 10.1016/0006‐2952(86)90769‐0; PUBMED: 3790168] ">Muth 1986</a>; <a href="./references#CD011091-bbs2-0054" title="MuthEA , MoyerJA , HaskinsJT . Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research1991;23(2):191‐9. [DOI: 10.1002/ddr.430230210] ">Muth 1991</a>). Its relatively clean pharmacological profile means that venlafaxine has a favourable adverse effect profile in comparison to other antidepressants used in pain management, especially the tricyclic antidepressants such as amitriptyline. The major metabolite, R‐O‐desmethylvenlafaxine, has been reported as the most potent inhibitor of both noradrenaline and serotonin reuptake (<a href="./references#CD011091-bbs2-0054" title="MuthEA , MoyerJA , HaskinsJT . Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Development Research1991;23(2):191‐9. [DOI: 10.1002/ddr.430230210] ">Muth 1991</a>). In 2010, this metabolite (desvenlafaxine) was approved by the US Food and Drug Administration as a treatment for major depressive disorder (<a href="./references#CD011091-bbs2-0062" title="SeoHJ , SohiMS , PatkarAA , MasandPS , PaeCU . Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. Postgraduate Medicine2010;122(1):125‐38. ">Seo 2010</a>). Relating steady‐state concentration of venlafaxine to in vitro reuptake inhibitory concentration suggests that serotonin reuptake is maximal at low doses (less than 100 mg/day), whereas noradrenaline reuptake increases over the dose range of 100 to 375 mg/day. Inhibition of both serotonin and noradrenaline reuptake is thought to be important for the antidepressant activity of venlafaxine. It is possible that similar mechanisms underlie any analgesic activity of venlafaxine, since both noradrenaline and serotonin are primary neurotransmitters in the inhibitory descending pain pathways of the locus coeruleus and Raphe nucleus, respectively. However, direct demonstrations of the mechanism of action of venlafaxine in the treatment of neuropathic pain are lacking and it is likely that the mechanism(s) underlying its analgesic effect differ from the mechanisms underlying its antidepressant effect. For example, in animal experiments, venlafaxine‐induced analgesia was reported to be mediated via adrenergic mechanisms and via the κ and δ opioid receptors (<a href="./references#CD011091-bbs2-0061" title="SchreiberS , BackerMM , PickCG . The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neuroscience Letters1999;273(2):85‐8. [DOI: 10.1016/S0304‐3940(99)00627‐8; PUBMED: 10505622] ">Schreiber 1999</a>). It is important to note that there tends to be little or no correlation between the effect of antidepressants on mood and pain in humans and that antidepressants can produce analgesia in people with and without depression, which further supports the notion that distinct mechanisms of action may underlie these effects (<a href="./references#CD011091-bbs2-0056" title="OnghenaP , VanHoudenhoveB . Antidepressant‐induced analgesia in chronic non‐malignant pain: a meta‐analysis of 39 placebo‐controlled studies. Pain1992;49(2):205‐19. [DOI: 10.1016/0304‐3959(92)90144‐Z; PUBMED: 1535121] ">Onghena 1992</a>). Furthermore, antidepressant‐induced pain relief typically emerges more rapidly and at a lower dose than the antidepressant effect, which often takes up to six weeks. </p> </section> <section id="CD011091-sec-0026"> <h3 class="title" id="CD011091-sec-0026">Why it is important to do this review</h3> <p>Venlafaxine is a reasonably well‐tolerated antidepressant and has been used as a pharmacological intervention for chronic neuropathic pain, although it is not a first‐line therapy at present. An update to an earlier Cochrane review of antidepressants for neuropathic pain reported preliminary evidence for the effectiveness of venlafaxine in relieving pain in polyneuropathy (<a href="./references#CD011091-bbs2-0060" title="SaartoT , WiffenPJ . Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2] ">Saarto 2007</a>). In animal studies, venlafaxine relieved thermal hyperalgesia in rats with an induced mononeuropathy (<a href="./references#CD011091-bbs2-0037" title="LangE , HordAH , DensonD . Venlafaxine hydrochloride (Effexor) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain1996;68:151‐5. [DOI: 10.1016/S0304‐3959(96)03223‐X; PUBMED: 9252010] ">Lang 1996</a>). Similarly in human experimental studies, venlafaxine reduced the threshold at which repetitive electrical stimulation showed pain summation (<a href="./references#CD011091-bbs2-0025" title="EnggaardTP , KlitgaardNA , GramLF , Arendt‐NielsenL , SindrupSH . Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. Clinical Pharmacology and Therapeutics2001;69(4):245‐51. [DOI: 10.1067/mcp.2001.114873; PUBMED: 11309553 ] ">Enggaard 2001</a>). Taken together and considering the current lack of effective treatments for neuropathic pain with favourable risk‐benefit ratios, there is good justification for conducting a comprehensive systematic review to establish whether an evidence base exists for the clinical use of venlafaxine in neuropathic pain management. This review will be one of several updates to the <a href="./references#CD011091-bbs2-0060" title="SaartoT , WiffenPJ . Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2] ">Saarto 2007</a> review of antidepressants in neuropathic pain. It will apply more stringent criteria for validity and may include new studies that have emerged since the 2007 update by Saarto and Wiffen. </p> <p>The standards used to assess evidence in chronic pain trials have changed substantially since 2008, because of an improved awareness of quality issues and the emergence of new recommendations by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT; <a href="./references#CD011091-bbs2-0024" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>), which is based on original work by <a href="./references#CD011091-bbs2-0026" title="FarrarJT , YoungJPJr , LaMoreauxL , WerthJL , PooleRM . Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale. Pain2011;94(2):149‐58. [PUBMED: 11690728] ">Farrar 2001</a>. Particular attention is now being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using mean pain scores, or mean change in pain scores, to the number of people who have a large decrease in pain (by at least 50%); this level of pain relief correlates with improvements in co‐morbid symptoms, function, and quality of life. These standards are set out in the reference guide for pain studies (<a href="./references#CD011091-bbs2-0020" title="PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 22 January 2013). ">AUREF 2012</a>). </p> <p>This Cochrane review assessed evidence in ways that make both statistical and clinical sense, and used developing criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD011091-bbs2-0045" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: doi:10.1016/j.pain.2010.05.011] '>Moore 2010a</a>). Trials included and analysed were required to meet a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc), and size (ideally at least 500 participants in a comparison in which the number needed to treat for an additional beneficial outcome (NNTB) is four or above (<a href="./references#CD011091-bbs2-0041" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>). This sets high standards and marks a departure from how reviews have been done previously. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011091-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011091-sec-0027"></div> <p>To assess the analgesic efficacy of, and the adverse effects associated with the clinical use of, venlafaxine for chronic neuropathic pain in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011091-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011091-sec-0028"></div> <section id="CD011091-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011091-sec-0030"> <h4 class="title">Types of studies</h4> <p>We included studies that were randomised controlled trials (RCTs) with double‐blind assessment of participant outcomes following two weeks of treatment or longer, though the emphasis of the review was intended to be on studies of eight weeks or longer. We required full journal publication, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials and abstracts with sufficient data for analysis. We did not include short abstracts (usually meeting reports). We excluded studies that were non‐randomised, studies of experimental pain, case reports, and clinical observations. </p> </section> <section id="CD011091-sec-0031"> <h4 class="title">Types of participants</h4> <p>All studies included adults aged 18 years and above. We considered studies if they had participants with one or more of a wide range of chronic neuropathic pain conditions including: </p> <p> <ul id="CD011091-list-0001"> <li> <p>painful diabetic neuropathy;</p> </li> <li> <p>postherpetic neuralgia;</p> </li> <li> <p>trigeminal neuralgia;</p> </li> <li> <p>phantom limb pain;</p> </li> <li> <p>postoperative or traumatic neuropathic pain;</p> </li> <li> <p>cancer‐related neuropathy;</p> </li> <li> <p>chemotherapy/radiotherapy‐induced neuralgia;</p> </li> <li> <p>atypical facial pain;</p> </li> <li> <p>complex regional pain syndrome;</p> </li> <li> <p>human immunodeficiency virus (HIV) neuropathy; and</p> </li> <li> <p>spinal cord injury.</p> </li> </ul> </p> <p>We included studies of participants with more than one type of neuropathic pain; in such cases, we planned to analyse results according to the primary condition. </p> </section> <section id="CD011091-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Venlafaxine at any dose, by any route, administered for the relief of neuropathic pain and compared with placebo or any active comparator. </p> </section> <section id="CD011091-sec-0033"> <h4 class="title">Types of outcome measures</h4> <p>Studies used a variety of outcome measures, with the majority of studies using standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS)) for pain intensity (VAS‐PI) or pain relief (VAS‐PR), or both. We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD011091-bbs2-0024" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>). These are defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on Patient Global Impression of Change (PGIC) (moderate), and very much improved on PGIC (substantial). These outcomes concentrate on dichotomous outcomes where pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50%, and with pain not worse than mild (<a href="./references#CD011091-bbs2-0055" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine2010;11(1):6‐15. [DOI: 10.1111/j.1526‐4637.2009.00685.x] ">O'Brien 2010</a>). </p> <p>We planned to include a 'Summary of findings' table as set out in the author guide (<a href="./references#CD011091-bbs2-0020" title="PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 22 January 2013). ">AUREF 2012</a>), but there were insufficient data. </p> <section id="CD011091-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011091-list-0002"> <li> <p>Participant‐reported pain relief of 30% or greater.</p> </li> <li> <p>Participant‐reported pain relief of 50% or greater.</p> </li> <li> <p>Participant‐reported global impression of change (PGIC) much or very much improved.</p> </li> <li> <p>Participant‐reported global impression of change (PGIC) very much improved.</p> </li> </ul> </p> </section> <section id="CD011091-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011091-list-0003"> <li> <p>Any pain‐related outcome indicating some improvement.</p> </li> <li> <p>Withdrawals due to lack of efficacy.</p> </li> <li> <p>Participants experiencing any adverse effect.</p> </li> <li> <p>Participants experiencing any serious adverse effect.</p> </li> <li> <p>Withdrawals due to adverse effects.</p> </li> <li> <p>Specific adverse effects, particularly somnolence and dizziness.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011091-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011091-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases with a start date of January 1990, because there are no earlier clinical trials of venlafaxine, which was developed in the late 1980s. Since the earliest clinical trials investigated its antidepressant activity, we did not miss any relevant studies by restricting the date of our searches to post‐1990. </p> <p> <ul id="CD011091-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via <i>The Cochrane Library</i> 2014, Issue 8 of 12; </p> </li> <li> <p>MEDLINE (via Ovid), January 1990 to 14 August 2014;</p> </li> <li> <p>EMBASE (via Ovid), January 1990 to 14 August 2014.</p> </li> </ul> </p> <p><a href="./appendices#CD011091-sec-0087">Appendix 2</a> shows the search strategies. We applied no language restrictions. We tailored the searches to the individual databases. </p> </section> <section id="CD011091-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We reviewed the bibliographies of any RCTs identified and review articles, contacted authors of one excluded study, and searched <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> to identify additional published or unpublished data. We also searched the meta‐Register of controlled trials (mRCT) (<a href="http://www.controlled-trials.com/mrct" target="_blank">www.controlled‐trials.com/mrct</a>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) for ongoing trials but did not find any relevant trials. </p> </section> </section> <section id="CD011091-sec-0039"> <h3 class="title" id="CD011091-sec-0039">Data collection and analysis</h3> <section id="CD011091-sec-0040"> <h4 class="title">Selection of studies</h4> <p>We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria and obtained full copies of the remaining studies. Three review authors (HCG, RMG, and MCH) read these studies independently and agreed on the study selection. We did not anonymise the studies before this assessment. </p> </section> <section id="CD011091-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (HCG, RMG, and MCH) independently extracted data using a standard form and checked for agreement before entry into Review Manager 5 (<a href="./references#CD011091-bbs2-0059" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We included information about the pain condition and number of participants treated, drug and dosing regimen, study design (placebo or active control), study duration and follow‐up, analgesic outcome measures and results, withdrawals, and adverse effects (participants experiencing any adverse effect or serious adverse effect). </p> </section> <section id="CD011091-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score as the basis for inclusion (<a href="./references#CD011091-bbs2-0032" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. [DOI: doi.org/10.1016/0197‐2456(95)00134‐4] ">Jadad 1996</a>), limiting inclusion to studies that were randomised and double‐blind as a minimum. We also used the 'Risk of bias' tool to assess the likely impact on the strength of the evidence of various study characteristics relating to methodological quality (randomisation, allocation concealment, blinding, freedom from selective reporting), study validity (duration, outcome reporting, and handling of missing data), and size (<a href="./references#CD011091-bbs2-0046" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010b</a>). </p> <p>Three review authors (HCG, MCH, and RMG) independently assessed the risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011091-bbs2-0030" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study: </p> <p> <ul id="CD011091-list-0005"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, eg random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We planned to exclude studies that used a non‐random process (eg odd or even date of birth; hospital or clinic record number), but this did not arise. </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (eg telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (eg open list). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed these methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, eg identical tablets; matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We excluded studies that were not, or appeared not to be, double‐blinded if we were unable to confirm double‐blinding by contact with the authors. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (less than 10% of participants did not complete the study, used 'baseline observation carried forward' analysis, or both); unclear risk of bias (used 'last observation carried forward' (LOCF) analysis); high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (200 or more participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm). </p> </li> </ul> </p> </section> <section id="CD011091-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to calculate the NNTB as the reciprocal of the absolute risk reduction (ARR) (<a href="./references#CD011091-bbs2-0039" title="McQuayH , MooreR . An Evidence‐Based Resource for Pain Relief. Oxford: Oxford University Press, 1998. ">McQuay 1998</a>). For unwanted effects, the NNTB becomes the number needed to treat for an additional harmful outcome (NNTH) and is calculated in the same manner. We planned to use dichotomous data to calculate risk ratio (RR) with 95% confidence intervals (CI) using a fixed‐effect model, unless we found significant statistical heterogeneity (see <a href="#CD011091-sec-0046">Assessment of heterogeneity</a>). We did not intend to use continuous data in analyses because it is inappropriate where there is an underlying skewed distribution. </p> </section> <section id="CD011091-sec-0044"> <h4 class="title">Unit of analysis issues</h4> <p>We accepted randomisation at the level of individual participants only and not at the level of treatment site. We split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis. For cross‐over studies, we intended to use data from only the first period if these were available and to treat the study as a parallel study. However, if only combined data for both periods were reported, we drew attention to the possible bias associated with interpretation of this data. </p> </section> <section id="CD011091-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>We planned to use intention‐to‐treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one post‐baseline assessment. We assigned missing participants to zero improvement. </p> </section> <section id="CD011091-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>We intended to deal with clinical heterogeneity by combining studies that examined similar conditions and to assess statistical heterogeneity visually (<a href="./references#CD011091-bbs2-0036" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta‐analysis in clinical research. Annals of Internal Medicine1987;107:224‐33. ">L'Abbé 1987</a>), and with the use of the I<sup>2</sup> statistic. However, this was not possible due to the small number of included studies. </p> </section> <section id="CD011091-sec-0047"> <h4 class="title">Assessment of reporting biases</h4> <p>The aim of this review was to use dichotomous data of known utility (<a href="./references#CD011091-bbs2-0046" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] ">Moore 2010b</a>). The review did not depend on what authors of the original studies chose to report or not, though clearly difficulties did arise in studies failing to report any dichotomous results. We extracted and used continuous data, which probably poorly reflect efficacy and utility, for illustrative purposes only. </p> <p>We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNTB of 10 or higher) (<a href="./references#CD011091-bbs2-0042" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5] ">Moore 2008</a>). </p> </section> <section id="CD011091-sec-0048"> <h4 class="title">Data synthesis</h4> <p>We planned to use a fixed‐effect model for meta‐analysis, or a random‐effects model if there was significant clinical heterogeneity and it was considered appropriate to combine studies. </p> <p>We analysed data for each painful condition in three tiers, according to outcome and freedom from known sources of bias. </p> <p>The first tier intended to use data meeting current best standards, where studies report the outcome of at least 50% pain intensity reduction over baseline (or its equivalent), without the use of LOCF or other imputation methods for drop‐outs, report an ITT analysis, last eight or more weeks, have a parallel‐group design, and have at least 200 participants (preferably at least 400) in the comparison (<a href="./references#CD011091-bbs2-0041" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD011091-bbs2-0045" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: doi:10.1016/j.pain.2010.05.011] '>Moore 2010a</a>; <a href="./references#CD011091-bbs2-0051" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265‐8. ">Moore 2012</a>). We intended to report these top‐tier results first. </p> <p>The second tier intended to use data from at least 200 participants, but where one or more of the conditions of the first tier was not met (eg reporting at least 30% pain intensity reduction, using LOCF or a completer analysis, or lasting four to eight weeks). </p> <p>The third tier of evidence relates to data from fewer than 200 participants, or where there were expected to be significant problems because, for example, of very short‐duration studies of less than four weeks, where there was major heterogeneity between studies, or where there were shortcomings in allocation concealment, attrition, or incomplete outcome data. For this third tier of evidence, no data synthesis is reasonable, and may be misleading, but an indication of beneficial effects might be possible. </p> </section> <section id="CD011091-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to undertake subgroup analysis for:</p> <p> <ul id="CD011091-list-0006"> <li> <p>dose of venlafaxine;</p> </li> <li> <p>different painful conditions.</p> </li> </ul> </p> </section> <section id="CD011091-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>This was not possible due to a small evidence base.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011091-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011091-sec-0051"></div> <section id="CD011091-sec-0052"> <h3 class="title">Description of studies</h3> <p>This review identified 14 clinical trials of venlafaxine in neuropathic pain, of which six met the criteria for inclusion. These six studies reported on 460 participants. </p> <section id="CD011091-sec-0053"> <h4 class="title">Results of the search</h4> <p>In total, the search identified 48 reports (after duplicates were removed) using the search criteria. However, many of these were small case reports, were of insufficient treatment duration, were open‐label studies, or involved other pain syndromes. As such, after screening titles and abstracts, only six studies met the inclusion criteria for analysis (<a href="#CD011091-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011091-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011091-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011091-sec-0054"> <h4 class="title">Included studies</h4> <p>The included studies comprised four cross‐over trials (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>; <a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a>; <a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a>; <a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a>), and two parallel trials (<a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a>; <a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a>). Doses used included 25 mg twice daily and 75, 150, and 225 mg once daily. The largest study was <a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a> with 245 participants. Three studies only reported mean data (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>; <a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a>; <a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a>). The earlier umbrella review did not include <a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a> (<a href="./references#CD011091-bbs2-0060" title="SaartoT , WiffenPJ . Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2] ">Saarto 2007</a>), but overall we did not find any more recent trials. Similarly, that previous umbrella Cochrane review included <a href="./references#CD011091-bbs2-0018" title="SimpsonDA . Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease2001;3(2):53‐62. ">Simpson 2001</a>, but we excluded it due to small participant numbers. </p> <p>Study participants were all over 18 years of age. Not all studies provided an age range, so the upper age limit was unclear but the mean age of participants taking venlafaxine ranged from 48 to 59 years and in all studies venlafaxine and control arms were age‐matched and sex‐matched appropriately. </p> </section> <section id="CD011091-sec-0055"> <h4 class="title">Excluded studies</h4> <p>Although included in a previous Cochrane review (<a href="./references#CD011091-bbs2-0060" title="SaartoT , WiffenPJ . Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2] ">Saarto 2007</a>) and another review (<a href="./references#CD011091-bbs2-0038" title="LeeY‐C , ChenP‐P . A review of SSRIs and SNRIs in neuropathic pain. Expert Opinion in Pharmacotherapy2010;11(17):2813‐25. [PUBMED: 20642317] ">Lee 2010</a>), <a href="./references#CD011091-bbs2-0017" title="ReubenSS , Makari‐JudsonG , LurieSD . Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of post‐mastectomy pain syndrome. Journal of Pain and Symptom Management2004;27(2):133‐9. [PUBMED: 15157037] ">Reuben 2004</a> was retracted due to falsification of data and is therefore excluded here. Durand and colleagues reported results of the EFFOX trial in which venlafaxine appeared to be effective in reducing oxiplatin‐induced neurosensory toxicity. However, the duration of treatment (10 days) was too short for inclusion in our analysis (<a href="./references#CD011091-bbs2-0010" title="DurandJP , DeplanqueG , MontheilV , GornetJM , ScotteF , MirO , et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin‐induced acute neurotoxicity: results of EFFOX, a randomized, double‐blind, placebo‐controlled phase III trial. Annals of Oncology2012;23(1):200‐5. ">Durand 2012</a>). Similarly, <a href="./references#CD011091-bbs2-0007" title="AmrYM , YousefAA . Evaluation of the efficacy of the perioperative administration of venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clinical Journal of Pain2010;26(5):381‐5. [PUBMED: 20473044] ">Amr 2010</a> reported some benefit for venlafaxine in treating chronic postmastectomy pain, but the duration of treatment was only 10 days and so we excluded this study. Although <a href="./references#CD011091-bbs2-0018" title="SimpsonDA . Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease2001;3(2):53‐62. ">Simpson 2001</a> reported the effectiveness of venlafaxine in addition to gabapentin in diabetic neuropathy, only seven participants were included in the venlafaxine arm and so we excluded this study as 10 per treatment group is the minimum we have considered. </p> </section> </section> <section id="CD011091-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>As summarised in <a href="#CD011091-fig-0002">Figure 2</a> and <a href="#CD011091-fig-0003">Figure 3</a>, the risk of bias was considerable overall in this systematic review and all studies had some shortcomings in this regard. </p> <div class="figure" id="CD011091-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011091-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011091-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011091-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011091-sec-0057"> <h4 class="title">Allocation</h4> <p>All studies that met the inclusion criteria were described as randomised. Selection bias was assessed by reviewing details of the randomisation of participants to study groups and the allocation concealment procedures. While four of the studies described all aspects of selection and concealment adequately and appeared to have a low risk of selection bias (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>; <a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a>; <a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a>; <a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a>), neither <a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a> nor <a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a> described this properly, and we deemed their risk of selection bias unclear. </p> </section> <section id="CD011091-sec-0058"> <h4 class="title">Blinding</h4> <p>Four of the included studies described the blinding procedure in detail so that it was clear that participants and investigators were unable to distinguish between active and control groups (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>; <a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a>; <a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a>; <a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a>). These four studies were deemed to present a low risk of performance and detection bias. However, <a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a> and <a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a> did not describe how their studies were blinded, although they did mention that their studies were double‐blinded. Therefore, the risk of bias was unclear for these two studies. </p> </section> <section id="CD011091-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>Only two of the six included studies had a low risk of attrition bias, since for both trials more than 90% of participants completed the trial (<a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a>; <a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a>). Both <a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a> and <a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a> had a greater than 10% drop‐out rate and only reported data for participants who completed trials and, therefore, we assessed them as being at high risk of bias. <a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a> and <a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a> were of intermediate or unclear risk of attrition bias. In both studies, more than 10% of participants did not complete the trial and LOCF analysis was employed. </p> </section> <section id="CD011091-sec-0060"> <h4 class="title">Selective reporting</h4> <p>While all studies reported the outcomes specified in their methods sections, these were not usually our preferred/primary outcome measures. Three of the included studies only reported mean data and did not provide an indication of how many participants improved according to our primary outcome measures (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>; <a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006;</a><a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a>). </p> </section> <section id="CD011091-sec-0061"> <h4 class="title">Other potential sources of bias</h4> <p>Although all included studies met the inclusion criterion of more than 10 participants randomised per treatment arm, lack of scale was a significant source of bias for all of them. Only <a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a> had more than 200 participants in total enrolled on the trial, but it still had fewer than 200 per treatment arm and, therefore, we considered it, along with <a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a>, at unclear risk of bias on the basis of size. Four of the included studies had fewer than 50 participants per treatment arm and we considered them at high risk of bias on the basis of size (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>; <a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a>; <a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a>; <a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a>). </p> </section> </section> <section id="CD011091-sec-0062"> <h3 class="title" id="CD011091-sec-0062">Effects of interventions</h3> <section id="CD011091-sec-0063"> <h4 class="title">First‐tier and second‐tier evidence of efficacy</h4> <p>We found no first‐tier or second‐tier evidence of efficacy. Of the six included studies, five had fewer than 200 participants, and the largest study employed LOCF analysis and was only of six weeks' duration (<a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a>). While small size was the primary problem with the included studies, short duration was also a major issue with only <a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a> reporting on the basis of eight weeks' treatment and none of the studies was of longer than eight weeks' duration. Problems with allocation concealment, attrition, or incomplete outcome data also marred most studies and led to a significant risk of bias (<a href="#CD011091-fig-0002">Figure 2</a>; <a href="#CD011091-fig-0003">Figure 3</a>). </p> </section> <section id="CD011091-sec-0064"> <h4 class="title">Third‐tier evidence of efficacy</h4> <p><a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a> recruited 245 adults with painful diabetic neuropathy who had experienced at least moderate neuropathic pain for at least three months and intended to treat 244 of those participants. Of these, 242 were treated and 202 completed the study. During the baseline two‐week period, their pain intensity was measured as at least 40 on the 0 to 100 VAS scale. Following randomisation to placebo, venlafaxine 75 mg, or venlafaxine 150 to 225 mg groups, their pain intensity and pain relief was measured using the VAS scales at week six. There was a significant reduction in pain intensity and a significant increase in pain relief with the higher dose of venlafaxine versus both placebo and lower dose of venlafaxine, but there were no significant differences in the frequency of adverse drug reactions (ADRs), serious ADRs, or withdrawals due to ADRs. </p> <p>Importantly, the percentage of participants considered to have responded to treatment, having achieved at least a 50% reduction from baseline on the VAS‐PI assessment, was significantly greater in the venlafaxine 150 to 225 mg group (56% of participants) compared with the placebo group (34% of participants) at week six. Furthermore, the overall reductions in pain intensity scores were 27% for placebo, 32% for venlafaxine 75 mg, and 50% for venlafaxine 150 to 225 mg, with only the higher dose of venlafaxine differing significantly from placebo. The NNTB was 4.5 for the higher dose of venlafaxine. Higher‐dose venlafaxine was also significantly better than placebo at mediating pain relief (VAS‐PR) after six weeks of treatment and it was superior to both venlafaxine 75 mg and placebo on the clinician‐rated Clinical Global Impressions ‐ Improvement (CGI‐I) and Clinical Global Impressions ‐ Severity (CGI‐S) items at week six. </p> <p><a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a> conducted a placebo‐controlled study in which venlafaxine 225 mg was compared with imipramine 150 mg in 40 participants with polyneuropathy. Fifteen of the participants for whom data were presented had diabetes‐related polyneuropathy. Both venlafaxine and imipramine were effective in producing at least moderate pain relief versus placebo, but notably there was no statistically significant difference between the two drugs. At least moderate pain relief was reported in 8/30 participants taking venlafaxine compared with 2/29 participants in the placebo arm of the study. This trial was stopped early due to insufficient supply of drugs. This was the only study that reported screening participants pharmacogenetically, such that those with low metabolism of sparteine were excluded. </p> <p>In one placebo‐controlled, cross‐over study of venlafaxine (dose up to 75 mg/day) in 30 participants with atypical facial pain, there was no significant reduction in pain intensity for venlafaxine, although there was a significant improvement in pain relief on the participant‐reported verbal rating scale (VRS) (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>). The authors also reported reduced use of escape medication (nonsteroidal anti‐inflammatory drugs and paracetamol) in the period when participants were taking venlafaxine versus placebo. </p> <p><a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a> compared venlafaxine and carbamazepine in a randomised, parallel trial of 132 participants with painful peripheral diabetic neuropathy, with diagnosis being confirmed by abnormal nerve conduction tests. In this double‐dummy design study, venlafaxine was dosed twice daily and the total daily dose was 50 mg. There was no placebo arm in this trial and only mean data were reported. Although not stated, the twice daily dosing probably reflected the use of an immediate‐release formulation versus extended‐release formulations of venlafaxine that are designed for once‐daily dosing. Although there was a significant reduction in pain intensity in both groups at five, seven, 10, and 14 days compared with their baseline scores, venlafaxine was superior to carbamazepine at reducing pain intensity at all time points by per‐protocol analysis, with an apparent reduction from 6.8 to 2.2 in mean pain intensity after 14 days of venlafaxine, measured on an 11‐point scale. Venlafaxine was also superior to carbamazepine at improving quality of life, measured as improved sleep, routine work, and mood. </p> <p><a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a> conducted a randomised, double‐blind cross‐over trial comparing venlafaxine and placebo in 15 women with neuropathic pain following breast cancer treatment. The treatment duration was four weeks per arm with a two‐week washout period between treatments and the dose of venlafaxine was escalated from 18.75 mg/day to a maximum of 37.5 mg (two participants) or 75 mg (11 participants). Primary outcome measures were current pain intensity during the last three days of the maximum tolerated dose (VAS‐PI and verbal rating scale ‐ pain intensity (VRS‐PI)) but these did not differ between treatment arms. Notably, there was a strong placebo effect. Using a computer program to register typical pain intensity in a diary format (VRS 0 to 7), the authors reported that 11 of the 13 participants who completed the trial had a least 50% pain relief and that this was significantly higher than pain relief reported in the placebo group. Notably, the 8‐point VRS used for current pain and the 5‐point VRS for current pain relief were non‐standard. Anxiety and depression scores were unaffected by either venlafaxine or placebo. </p> <p><a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a> performed a randomised double‐blind, placebo‐controlled parallel trial with 60 participants with neuropathic pain assigned to venlafaxine 75 mg, venlafaxine 150 mg, or placebo for eight weeks. Sixteen of the 60 participants had diabetic polyneuropathy but results were not stratified according to type of neuropathic pain. A major focus of this trial was effects of venlafaxine on experimentally induced pain, which was not of interest to us. However, effects on ongoing pain intensity (VAS 0 to 10), activities of daily living, adverse effects, and global efficacy and tolerance were also reported. Although VAS‐PI scores decreased significantly from baseline in all participant groups, they did not differ between treatment arms. Since only mean data were reported, it was impossible to estimate the proportion of participants achieving moderate (or better) pain relief. In terms of global efficacy and tolerance, there was no difference between groups. </p> </section> <section id="CD011091-sec-0065"> <h4 class="title">Adverse effects</h4> <p>All studies included in this review made some mention of adverse effects, but reporting of these was not standardised across studies and it was impossible to perform a meta‐analysis of this data. In general, venlafaxine was well tolerated and most adverse effects were minor. </p> <p><a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a> asked participants about 10 adverse effects (urination difficulties, fatigue, appetite, dry mouth, constipation, sweating, nightmares, nausea, headache, and palpitations) and asked participants to self evaluate the overall severity of these adverse effects on a 100‐mm VAS. Overall, the incidence of adverse effects was similar in the venlafaxine and placebo periods but participants reported more severe dry mouth and sweating while taking venlafaxine compared with placebo. </p> <p><a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a> reported 29 adverse effects in the venlafaxine group, with these affecting 43.9% of participants. Common adverse effects were reported as those occurring in more than 10% of participants and these included mild gastrointestinal discomfort, dizziness, and somnolence. However, as this trial was not placebo‐controlled, it is difficult to draw a definitive conclusion. Severe gastrointestinal disturbance occurred in one participant on venlafaxine. </p> <p><a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a> reported treatment‐emergent adverse effects in 75% of participants on placebo, 88% of participants on venlafaxine 75 mg, and 89% of participants on venlafaxine 150 to 225 mg. Nausea, dyspepsia, sweating, and somnolence were the most commonly reported and all of these were significantly more frequent in at least one of the venlafaxine groups versus placebo. The same authors reported that 10% of placebo, 9% of venlafaxine 75 mg and 12% of venlafaxine 150 to 225 mg groups had a serious adverse effect, although their precise nature was unclear. They also reported that 7/162 participants who commenced venlafaxine had clinically important electrocardiograph (ECG) changes over the course of their treatment. </p> <p><a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a> asked participants to rate adverse effects as none, slight, bothersome, or unacceptable. However, adverse‐effect ratings were not different between the venlafaxine, imipramine, and placebo arms of this study. They also reported incidence rates of specific adverse effects and suggested that venlafaxine was less well tolerated than imipramine on the basis of withdrawals due to adverse effects, and that it was associated with a higher incidence of tiredness than either placebo or imipramine. </p> <p><a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a> reported no differences in either the number or intensity of adverse effects between venlafaxine and placebo treatment arms. Participants were asked about the same 10 adverse effects as those in the <a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a> study, and they recorded both responses and spontaneous reports of the adverse effects. </p> <p><a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a> mentioned nausea, vomiting, somnolence, and dizziness as occurring more commonly in the venlafaxine 150 mg group, but, since data only consisted of participant reports of none, slight, bothersome, or unacceptable adverse effects, it was unclear how many participants experienced each of these adverse effects. </p> </section> <section id="CD011091-sec-0066"> <h4 class="title">Withdrawals</h4> <p><a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a> reported 10 drop‐outs from 30 participants who had commenced their cross‐over study. Eight participants dropped out due to adverse effects and six of these did so while taking venlafaxine (five due to nausea and one due to fatigue). They withdrew two participants due to non‐compliance and one of these drop‐outs was reported as being due to lack of efficacy. </p> <p><a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a> noted five withdrawals among 60 participants who started the trial, with all being due to adverse effects. Of interest, three of the five withdrawals were in the venlafaxine 150 mg group and one was from the venlafaxine 75 mg group, consistent with the earlier comment on the higher prevalence of adverse effects associated with the higher dose of venlafaxine. </p> <p>In the study by <a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a>, there was a relatively small drop‐out rate of less than 10% in the venlafaxine group, which reduced the attrition bias compared with other studies. Six participants withdrew from 66 who commenced on venlafaxine, and four of these withdrawals were due to adverse effects (one participant with severe gastrointestinal disturbance, one participant with palpitations, and two participants with moderate gastrointestinal disturbance). </p> <p><a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a> reported relatively high discontinuation rates of 15% with placebo, 15% with venlafaxine 75 mg, and 22% with venlafaxine 150 to 225 mg and these discontinuation rates did not differ significantly between the groups. In addition, there was no difference between venlafaxine and placebo groups in the rate of drop‐outs due to adverse effects. Overall, 14 participants taking either venlafaxine 75 mg or 150 to 225 mg withdrew due to adverse effects and 30/163 participants on venlafaxine withdrew in total. Five participants on venlafaxine were withdrawn due to inadequate efficacy, three due to protocol violations, three due to other medical events, one due to a non‐medical event, three were lost to follow‐up, and one requested to withdraw for unclear reasons. </p> <p>In the cross‐over study by <a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a>, there were seven reported drop‐outs from 40 participants who commenced the study and one additional participant was excluded on the basis of unacceptably high tramadol consumption. Of the seven drop‐outs, four withdrew while taking venlafaxine due to nausea, vomiting, dizziness, tiredness, or combinations thereof. The other three participants withdrew while in the non‐venlafaxine arm. </p> <p><a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a> reported two drop‐outs from 15 participants who started the study. One was due to non‐compliance and the other due to acute nausea, sweating, and headache that started on the first day of venlafaxine 18.75 mg plus 37.5 mg dose. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011091-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011091-sec-0067"></div> <section id="CD011091-sec-0068"> <h3 class="title" id="CD011091-sec-0068">Summary of main results</h3> <p>Overall, it was notable that all included studies showed some positive benefit for venlafaxine in neuropathic pain. Positive outcomes included reduced use of escape medication, such as paracetamol, and reductions in pain intensity scores of less than 50%. Notably, in the largest included study, the percentage of participants considered to have responded to treatment, having achieved at least a 50% reduction in pain intensity, was significantly greater in the venlafaxine 150 to 225 mg group (56% of participants) compared with the placebo group (34% of participants) (<a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a>). However, we did not deem this to constitute strong evidence for the efficacy of this intervention, since the study was subject to significant bias (<a href="#CD011091-fig-0003">Figure 3</a>). </p> </section> <section id="CD011091-sec-0069"> <h3 class="title" id="CD011091-sec-0069">Overall completeness and applicability of evidence</h3> <p>Since the two largest of the included studies only looked at diabetes‐associated neuropathy (<a href="./references#CD011091-bbs2-0002" title="JiaH‐Y , LiQ‐F , SongD‐P , AnZ‐M , LiuY‐P , RanX‐W , et al. Effects of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: a randomized, double‐blind and double‐dummy, controlled multi‐center trial. Chinese Journal of Evidence‐Based Medicine2006;6(5):321‐7. ">Jia 2006</a>; <a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a>), and overall more than 80% of included participants had diabetes, it is possible that any benefits shown for venlafaxine may not be applicable to other painful neuropathic conditions. Other specific types of neuropathic pain for which the efficacy of venlafaxine was assessed were atypical facial pain (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>), and postoperative/post‐chemotherapy neuralgia in people with breast cancer (<a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a>). However, both studies were hampered by very small numbers of participants. A further confounding factor was the complex interaction between depression and pain as venlafaxine is an established and effective antidepressant drug and not all studies measured depression at baseline or accounted for the fact that relief of depression may have a positive benefit on pain scores. Applicability of these trials was further hampered by their short duration since only one trial was of six weeks' duration (<a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a>), and none was longer than this. It is thought that studies of less than six weeks' duration may not accurately predict longer‐term drug efficacy in chronic conditions, as epitomised by neuropathic pain. Similarly, short‐term use of drugs may not accurately predict ADRs that emerge with longer‐term drug dosing in chronic illness. </p> </section> <section id="CD011091-sec-0070"> <h3 class="title" id="CD011091-sec-0070">Quality of the evidence</h3> <p>By current standards, the overall reporting quality was average to poor. Although all included studies were randomised and double‐blinded, none of them provided data that met pre‐defined criteria for first‐tier or second‐tier analysis. Only two studies had more than 50 participants per treatment arm and four studies were significantly smaller than that and therefore presented a high risk of bias on the basis of size. Five of six studies were of short duration and four were of cross‐over design. Only one study was both parallel in design and placebo‐controlled. All studies used completer analysis or LOCF analyses so that only those with greater than 90% completion were not at risk of attrition bias. </p> </section> <section id="CD011091-sec-0071"> <h3 class="title" id="CD011091-sec-0071">Potential biases in the review process</h3> <p>In accordance with most Cochrane reviews completed by the Pain, Palliative and Supportive Care Review Group (PaPaS), we included only randomised double‐blind studies in an effort to limit the potential for bias. However, there were several other sources of bias. </p> <p>The absence of publication bias, whereby studies showing a lack of efficacy for venlafaxine are performed but not published, cannot be proven. However, this is an inherent weakness in all systematic reviews. Nonetheless, it is considered unlikely that we have missed any published evidence, since we carried out several broad searches and we believe it is unlikely that significant amounts of data eluded us in these searches. </p> <p>NNTB estimates of efficacy in chronic pain tend to increase with duration of trials, meaning that participants tend to derive less benefit as trials proceed (<a href="./references#CD011091-bbs2-0045" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain2010;150(3):386‐9. [DOI: doi:10.1016/j.pain.2010.05.011] '>Moore 2010a</a>). This means that the short duration of all included studies is particularly problematic here and that these studies are likely to have significantly over‐estimated the efficacy of venlafaxine in treating chronic pain. </p> </section> <section id="CD011091-sec-0072"> <h3 class="title" id="CD011091-sec-0072">Agreements and disagreements with other studies or reviews</h3> <p>This review does not change the conclusion drawn in an earlier review (<a href="./references#CD011091-bbs2-0060" title="SaartoT , WiffenPJ . Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2] ">Saarto 2007</a>). Moreover, current treatment guidelines for neuropathic pain in Europe and the USA do not specifically recommend prescription of venlafaxine. Another review of selective serotonin re‐uptake inhibitors (SSRIs) and serotonin and noradrenaline re‐uptake inhibitors (SNRIs) in neuropathic pain concluded that there was only modest evidence for the efficacy of SSRIs overall, but that the SNRIs (ie venlafaxine and duloxetine) were effective in the treatment of painful diabetic neuropathy and polyneuropathy (<a href="./references#CD011091-bbs2-0038" title="LeeY‐C , ChenP‐P . A review of SSRIs and SNRIs in neuropathic pain. Expert Opinion in Pharmacotherapy2010;11(17):2813‐25. [PUBMED: 20642317] ">Lee 2010</a>). Notably that review, although not conducted systematically, considered several of our included studies (<a href="./references#CD011091-bbs2-0001" title="ForssellH , TasmuthT , TenovuoO , HampfG , KalsoE . Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. Journal of Orofacial Pain2004;18(2):131‐7. [PUBMED: 15250433] ">Forssell 2004</a>; <a href="./references#CD011091-bbs2-0003" title="RowbothamMC , GoliV , KunzNR , LeiD . Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double‐blind, placebo‐controlled study. Pain2004;110(3):697‐706. ">Rowbotham 2004</a>; <a href="./references#CD011091-bbs2-0004" title="SindrupSH , BachFW , MadsenC , GramLF , JensenTS . Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology2003;60(8):1284‐9. ">Sindrup 2003</a>; <a href="./references#CD011091-bbs2-0005" title="TasmuthT , HärtelB , KalsoE . Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain2002;6(1):17‐24. ">Tasmuth 2002</a>; <a href="./references#CD011091-bbs2-0006" title="YucelA , OzyalcinS , TaluGK , KiziltanE , YucelB , AndersenOK , et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. European Journal of Pain2005;9(4):407‐16. ">Yucel 2005</a>), however it also included data from <a href="./references#CD011091-bbs2-0017" title="ReubenSS , Makari‐JudsonG , LurieSD . Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of post‐mastectomy pain syndrome. Journal of Pain and Symptom Management2004;27(2):133‐9. [PUBMED: 15157037] ">Reuben 2004</a> and <a href="./references#CD011091-bbs2-0018" title="SimpsonDA . Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. Journal of Clinical Neuromuscular Disease2001;3(2):53‐62. ">Simpson 2001</a>, which we excluded due to our more stringent inclusion criteria. In their general literature reviews, not conducted along Cochrane principles, <a href="./references#CD011091-bbs2-0038" title="LeeY‐C , ChenP‐P . A review of SSRIs and SNRIs in neuropathic pain. Expert Opinion in Pharmacotherapy2010;11(17):2813‐25. [PUBMED: 20642317] ">Lee 2010</a> and <a href="./references#CD011091-bbs2-0023" title="DharmshaktuP , TayalV , SinghKB . Efficacy of antidepressants as analgesics: a review. Journal of Clinical Pharmacology2012;52:6‐17. [PUBMED: 21415285] ">Dharmshaktu 2012</a> also arrived at a similar conclusion to us that while SNRIs, including venlafaxine, may have some place in treating neuropathic pain, they should probably only be considered for use in people who have not responded to tricyclic antidepressants and anticonvulsants, or if there are contraindications to these better‐established drugs. </p> <p>Another issue that may have accounted for heterogeneity in the clinical findings is that there is very little standardisation of medication history and usage in chronic pain trials. Some trials preclude those people taking other analgesics, anticonvulsants, or antidepressants during or preceding the trial, while others allow the use of escape medication for analgesia as well as other concurrent medications. This is highly likely to confound study findings and makes it more difficult to compare studies directly. Use of escape medication in pain trials is considered a secondary outcome measure and two of our included studies reported that venlafaxine reduced the usage of alternative analgesics during the study period, which gives some weak indication of potential efficacy in treating neuropathic pain. </p> <p>Depression and anxiety scores were also reported in some, but not all, of the reviewed studies. Due to the complex nature of pain it is considered likely that clinical improvements in anxiety and depression may be accompanied by participant‐reported improvements in pain intensity and it can be difficult to separate these complex phenomena. Due to the small number of studies reviewed here, no clear pattern emerged relating the antidepressant efficacy of venlafaxine to its analgesic efficacy; however, it is a factor that should be considered in any review of antidepressants in pain management. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011091-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/urn:x-wiley:14651858:media:CD011091:CD011091-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_t/tCD011091-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011091-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011091-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/urn:x-wiley:14651858:media:CD011091:CD011091-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_t/tCD011091-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011091-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011091-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/urn:x-wiley:14651858:media:CD011091:CD011091-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_t/tCD011091-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011091-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/full#CD011091-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011091.pub2/media/CDSR/CD011091/image_n/nCD011091-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011091.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011091-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011091-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011091-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011091-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011091\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011091\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011091\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011091\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011091.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011091.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011091.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011091.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011091.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715742904"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011091.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715742907"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011091.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8e6bbcdbf55f',t:'MTc0MDcxNTc0My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 